Daniel Gingerich DVM, IMULAN’s Chief Scientific Officer stated, “It has been confirmed that T-cell abnormalities represent an underlying immunological defect in atopic dermatitis. This new diagnostic detects hyper-reactivity to the dogs’ own T-cell receptors, which appears to be a characteristic of atopic dermatitis.”
Canine atopic dermatitis is a prevalent condition in dogs affecting 5% or more of the dog population. Atopic dermatitis in dogs is comparable to human atopic dermatitis and eczema, including alterations in immune profiles and sensitivity to allergens. Clinical signs of atopic dermatitis include pruritus (itching) and an increase in topical skin infections such as staphylococcal pyoderma.
About IMULAN: Imulan develops unique, precision immune regulating compounds for veterinary medicine. IMULAN’s primary focus is on immunological strategies to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN has active therapeutic programs for atopic dermatitis and feline stomatitis using their T-Cell receptor peptide platform. For more information about Imulan, please visit www.IMULAN.com
